NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) today announced the commercial launch of ERBITUX® (cetuximab) in Canada for use in the treatment of metastatic colorectal cancer (mCRC). Bristol-Myers Squibb collaborates with ImClone on ERBITUX in North America and is making the product commercially available through its wholly-owned subsidiary Bristol-Myers Squibb Canada.
